Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

June 30, 2008

Conditions
Carcinoma, Small CellSmall Cell Lung Cancer
Interventions
DRUG

SNS-595

Trial Locations (17)

10021

Memorial Sloan-Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore

27705

Duke University Medical Center, Durham

37203

Sarah Cannon Research Institute, Nashville

37232

The Vanderbilt-Ingram Cancer Center, Nashville

60612

Rush University Medical Center, Chicago

94305

Stanford University Medical Center, Stanford

95817

University of California Davis, Sacramento

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

J4V 2H1

Hopital Charles LeMoyne, Greenfield Park

G1V 4G5

Hopital Laval, Sainte-Foy

Sponsors
All Listed Sponsors
lead

Sunesis Pharmaceuticals

INDUSTRY